Triple nucleoside analogue vs. efavirenz-containing regimens for the initial treatment of HIV infection: AIDS Clinical Trials Group (ACTG) Study A5095

RM Gulick, H Ribaudo, CM Shikuma, S Lustgarten, K Squires, WA Meyer, E Acosta, BR Schackman, CD Pilcher, RL Murphy, WE Maher, M Witt, RC Reichman, S Snyder, KL Klingman, DR Kurizkes, for the ACTG A5095 Protocol Team

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)32-43
Number of pages12
JournalN Engl J Med
Issue number350
StatePublished - 2004

Cite this

Gulick, RM., Ribaudo, H., Shikuma, CM., Lustgarten, S., Squires, K., Meyer, WA., Acosta, E., Schackman, BR., Pilcher, CD., Murphy, RL., Maher, WE., Witt, M., Reichman, RC., Snyder, S., Klingman, KL., Kurizkes, DR., & Team, F. T. ACTG. A. P. (2004). Triple nucleoside analogue vs. efavirenz-containing regimens for the initial treatment of HIV infection: AIDS Clinical Trials Group (ACTG) Study A5095. N Engl J Med, (350), 32-43.